Oncocyte (NASDAQ:IMDX) Stock Rating Lowered by Wall Street Zen

Oncocyte (NASDAQ:IMDX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Oncocyte presently has a consensus rating of “Hold” and an average target price of $12.00.

Oncocyte Price Performance

Shares of IMDX opened at $4.32 on Friday. Oncocyte has a 1-year low of $2.33 and a 1-year high of $8.51. The stock has a market cap of $141.35 million, a PE ratio of -2.90 and a beta of 1.79. The firm has a 50-day simple moving average of $5.08 and a two-hundred day simple moving average of $5.07.

Oncocyte (NASDAQ:IMDX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million for the quarter.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.